Reaktionsgleichung
I[C:2]1[CH:7]=[CH:6][N:5]([CH2:8][CH2:9][C@@:10]([CH3:25])([S:21]([CH3:24])(=[O:23])=[O:22])[C:11]([NH:13][O:14][C@@H]2CCCCO2)=[O:12])[C:4](=[O:26])[CH:3]=1.CC1(C)C(C)(C)OB([C:35]2[CH:55]=[CH:54][C:38]([O:39][CH2:40][C@H:41]3[CH2:46][CH2:45][C@H:44]([O:47]C4CCCCO4)[CH2:43][CH2:42]3)=[CH:37][CH:36]=2)O1.C(N)(=O)CCC>>[OH:14][NH:13][C:11](=[O:12])[C@:10]([CH3:25])([S:21]([CH3:24])(=[O:22])=[O:23])[CH2:9][CH2:8][N:5]1[CH:6]=[CH:7][C:2]([C:35]2[CH:36]=[CH:37][C:38]([O:39][CH2:40][C@H:41]3[CH2:46][CH2:45][C@H:44]([OH:47])[CH2:43][CH2:42]3)=[CH:54][CH:55]=2)=[CH:3][C:4]1=[O:26]Komponenten
4
Versuchsvorschrift
The title compound (489 mg, 49.7%) was prepared from (2R)-4-(4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-[(2R)-tetrahydro-2H-pyran-2-yloxy]butanamide (742 mg, 1.49 mmol) and 2-[(trans-4-{[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl}cyclohexyl)oxy]tetrahydro-2H-pyran (620 mg, 1.49 mmol) by a procedure analogous to that described for (2R)-2-methyl-2-(methylsulfonyl)-4-[2-oxo-4-(4-{[cis-4-(tetrahydro-2H-pyran-2-yloxy)cyclohexyl]methoxy}phenyl)pyridin-1(2H)-yl]-Netrahydro-2H-pyran-2-yloxy)butanamide, Example 8, Step E. LCMS m/z 659.8 (M−1).
Quellen und Nachweise
- ORD-Eintrag
- ord-e9692c688b4848819f9c9c75684ced23
- Quelldatensatz
- uspto-grants-2015_04
- Patentnummer
- US09018384B2
Verknüpfte Notizen
Wird geladen…